<DOC>
	<DOCNO>NCT01526512</DOCNO>
	<brief_summary>The purpose study evaluate role low dose metronomic cyclophosphamide capecitabine pretreated metastatic breast cancer .</brief_summary>
	<brief_title>Low Dose Metronomic Cyclophosphamide Capecitabine Pretreated HER2-negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Metronomic chemotherapy consider effective strategy metastatic breast cancer . This trial design evaluate role low dose metronomic cyclophosphamide capecitabine pretreated metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Females age 18 80 year old 2 . ECOG performance 03 3 . Life expectancy 3 month 4 . Histological proven unresectable recurrent advance HER2negative breast cancer 5 . At least one previous therapy regimen ( include endocrine therapy ) metastatic breast cancer ; suitable monotherapy ( Neoadjuvant adjuvant docetaxel complete least one year ) . 6 . At least one measurable disease accord response evaluation criterion solid tumor ( RECIST1.1 ) 7 . No anticancer therapy within 4 week 8 . Adequate hematologic , hepatic , renal function , No serious medical history heart , lung , liver kidney 9 . Provision write informed consent prior study specific procedures 10 . Previous capecitabine permit , however , complete least 6 month . 1 . Pregnant lactate woman ( female patient childbearing potential must negative serum pregnancy test within 14 day first day drug dosing , , positive , pregnancy rule ultrasound ) 2 . Women childbearing potential , unwilling use adequate contraceptive protection course study 3 . Treatment investigational product within 4 week first treatment 4 . Symptomatic central nervous system metastases 5 . Other active malignancy ( include hematologic malignancy ) malignancy , except cure nonmelanoma skin cancer cervical intraepithelial neoplasia . 6 . Patient history clinically significant cardiovascular , hepatic , respiratory renal disease , clinically significant hematological endocrinal abnormality , clinically significant neurological psychiatric condition 7 . Uncontrolled serious infection 8 . Patients bad compliance 9 . Patients lack Dihydropyrimidine Dehydrogenase ( DPD )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Metronomic cyclophosphamide</keyword>
	<keyword>Metronomic capecitabine</keyword>
	<keyword>HER2-negative breast cancer</keyword>
</DOC>